Thyas Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 42

Employees

  • Latest Deal Type
  • M&A

Thyas General Information

Description

Developer of a cell regenerative method designed for curing cancer and other infectious diseases. The company develops regenerative T cells from human iPS cells and provides personalized regenerative immuno-cell therapy, helping patients in the treatment of cancer.

Contact Information

Website
www.thyas.co.jp
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 46-29 Yoshidashimoadachi Sakyo-ku
  • University Med-Pharm Collaboration Building
  • Kyoto, Kyoto 606-8501
  • Japan
+81
Primary Industry
Biotechnology
Acquirer
Shinobi Therapeutics
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 46-29 Yoshidashimoadachi Sakyo-ku
  • University Med-Pharm Collaboration Building
  • Kyoto, Kyoto 606-8501
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thyas Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 12-Dec-2023 Completed Generating Revenue
6. Later Stage VC (Series B) 18-Feb-2022 Completed Generating Revenue
5. Later Stage VC (Series A3) 01-Oct-2021 Completed Generating Revenue
4. Early Stage VC (Series A2) 20-Nov-2019 Completed Generating Revenue
3. Early Stage VC 28-Jun-2019 Completed Generating Revenue
2. Seed Round 15-Nov-2017 $1.76M $1.76M Completed Startup
1. University Spin-Out 24-Aug-2015 Completed Startup
To view Thyas’s complete valuation and funding history, request access »

Thyas Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B preferred
A3 preferred
A2 preferred 40,001 $52.2 $52.2 1x $52.2 6.97%
A1 preferred 36,000 $47.85 $47.85 1x $47.85 6.28%
To view Thyas’s complete cap table history, request access »

Thyas Patents

  • 49

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Thyas Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023249071-A1 T-cell receptor Inactive 24-Jun-2022
CA-3213440-A1 A cell bank composed of ips cells for transfecting t cell receptor gene Pending 16-Apr-2021
AU-2022259170-A1 Cell bank composed of ips cells for introducing t cell receptor gene Pending 16-Apr-2021
EP-4324917-A1 Cell bank composed of ips cells for introducing t cell receptor gene Pending 16-Apr-2021
EP-4324917-A4 Cell bank composed of ips cells for introducing t cell receptor gene Pending 16-Apr-2021 C07K16/104
To view Thyas’s complete patent history, request access »

Thyas Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thyas Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
CITIC Capital Asset Manager Minority
Chushin Venture Capital Corporate Venture Capital Minority
D3 (Tokyo) Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
F-Prime Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Thyas FAQs

  • When was Thyas founded?

    Thyas was founded in 2015.

  • Where is Thyas headquartered?

    Thyas is headquartered in Kyoto, Japan.

  • What is the size of Thyas?

    Thyas has 42 total employees.

  • What industry is Thyas in?

    Thyas’s primary industry is Biotechnology.

  • Is Thyas a private or public company?

    Thyas is a Private company.

  • What is Thyas’s current revenue?

    The current revenue for Thyas is .

  • How much funding has Thyas raised over time?

    Thyas has raised $27M.

  • Who are Thyas’s investors?

    CITIC Capital, Chushin Venture Capital, D3 (Tokyo), Eight Roads, and F-Prime are 5 of 9 investors who have invested in Thyas.

  • When was Thyas acquired?

    Thyas was acquired on 12-Dec-2023.

  • Who acquired Thyas?

    Thyas was acquired by Shinobi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process